Pivotal Study of Eisai's Partial Epilepsy Treatment Fycompa® (perampanel) Published in Neurology®

Pivotal Study of Eisai's Partial Epilepsy Treatment Fycompa® (perampanel) Published in Neurology® PR Newswire HATFIELD, England, July 26, 2012 HATFIELD, England, July 26, 2012 /PRNewswire/ -- Eisai today announces the publication of results from a pivotal Phase III study[1] of Fycompa® (perampanel), the first in a new class of adjunctive treatment in people with partial-onset seizures, with or without secondary generalised seizures, aged 12 years and older. According to research published in the August 2012 issue of Neurology®, the medical journal of the American Academy of Neurology, the Study 304 data, published online today show that once-daily, adjunctive perampanel at doses of 8 or 12mg improved seizure control in people with uncontrolled partial-onset seizures, and that both doses had an acceptable safety and tolerability profile. Study 304 is one of three pivotal Phase III studies in the EXPLORE (EXamining Perampanel Observations from Research Experience) clinical trial programme. The successful treatment of partial-onset seizures (the most common type of epilepsy) remains a challenge in some people. The incidence of uncontrolled epilepsy remains high despite many new anti-epileptic drugs (AEDs) and it is estimated that the proportion of people diagnosed with epilepsy who, are or will become, refractory to treatment range from 20% to as high as 40%.